Create issue ticket

548 Possible Causes for 90, Y, ibritumomab, tiuxetan, yttrium

Show results in: Română

  • Follicular Lymphoma

    , Yamasaki R 1 , Kawasaki Y 1 , Sugimoto M 1 , Ashizawa M 1 , Yamamoto C 1 , Hatano K 1 , Sato K 1 , Oh I 1 , Ohmine K 1 , Muroi K 1 , Kanda Y 2 .[ncbi.nlm.nih.gov] Abstract Yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed[ncbi.nlm.nih.gov] ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90[zevalin.com] PURPOSE: We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients[ncbi.nlm.nih.gov] Radioisotopes/adverse effects Yttrium Radioisotopes/therapeutic use Substances Antibodies, Monoclonal Yttrium Radioisotopes Rituximab ibritumomab tiuxetan Vidarabine fludarabine[ncbi.nlm.nih.gov]

  • Iodine-131-Tositumomab

    Y 90 ibritumomab tiuxetan Y 90 ibritumomab tiuxetan was approved for marketing in 2002 by the FDA, the first in kind, with an indication for the treatment of patients with[nature.com] It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002.[secure.medicalletter.org] Abstract We retrospectively evaluated our single-center clinical experi-ence with 90Y-ibritumomab tiuxetan and 131I-tositumomab for therapy of refractory non-Hodgkin’s lymphoma[citeseerx.ist.psu.edu] Large B-Cell Lymphoma (DLBCL) The results from this Phase II study from SWOG are in contrast to a study at Memorial Sloan-Kettering, where we administered R-CHOP followed by yttrium[slideplayer.com] […] patients with relapsed B-cell lymphomas. 18 , 19 Studies using radioimmunotherapy at nonmyeloablative doses have produced response rates of 60% to 80% for iodine-131 and yttrium[dx.doi.org]

  • Non-Hodgkin Lymphoma

    Sano Y 1 , Nakano Y , Omoto M , Takao M , Ikeda E , Oga A , Nakamichi K , Saijo M , Maoka T , Sano H , Kawai M , Kanda T .[ncbi.nlm.nih.gov] Radioisotopes/administration & dosage* Substances Antibodies, Monoclonal Yttrium Radioisotopes Cytarabine Yttrium-90 ibritumomab tiuxetan Podophyllotoxin Melphalan Carmustine[ncbi.nlm.nih.gov] The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and 90 Y ibritumomab tiuxetan regimen. 90 Y ibritumomab tiuxetan was routinely[doi.org] Results: Over 24-30 y of follow-up, neither total nor specific dietary fats were significantly associated with NHL risk overall.[ncbi.nlm.nih.gov] 22 , Benoit Y 3 ; Children–s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC) .[ncbi.nlm.nih.gov]

  • B-Cell Non-Hodgkin Lymphoma

    Uike N 1 , Choi I , Tsuda M , Haji S , Toyoda K , Suehiro Y , Abe Y , Hayashi T , Sawamoto H , Kaneko K , Shimokawa M , Nakagawa M .[ncbi.nlm.nih.gov] Yttrium Y 90-ibritumomab tiuxetan is an example of a radiolabeled monoclonal antibody. Monoclonal antibodies are given by infusion .[cancer.gov] Forty-seven (90 %) patients completed four cycles of treatment as per schedule.[ncbi.nlm.nih.gov] 14 , Komada Y 15 , Saito AM 16 , Nakazawa A 17 , Horibe K 16 ; lymphoma committee of the Japanese Pediatric Leukemia/lymphoma Study Group .[ncbi.nlm.nih.gov] This might include either rituximab for up to 2 years or treatment with ibritumomab tiuxetan.[cancer.org]

  • Tenecteplase

    Se presenta el caso de un paciente varón de 50 años de edad con TEP aguda y un trombo en tránsito en la aurícula derecha.[biblat.unam.mx] Ibritumomab Tiuxetan: (Major) During and after therapy, avoid the concomitant use of Yttrium (Y)-90 ibrutumomab tiuxetan with drugs that interfere with coagulation such as[pdr.net] Overall, 66% had excellent functional outcome (modified Rankin Scale, 0-1) at 90 days.[ncbi.nlm.nih.gov] Mean patient age was 44 years (range, 0-92 y); 72 patients (29%) were younger than 17 years of age. Chemotherapy was the most common reason for catheter insertion.[ncbi.nlm.nih.gov] The safety endpoints were death rate at 90 days and symptomatic intracranial hemorrhage (SICH).[ncbi.nlm.nih.gov]

  • Adult T-Cell Leukemia - Lymphoma

    Y , Noguchi H , Takahashi H .[ncbi.nlm.nih.gov] Yttrium Y 90-ibritumomab tiuxetan is an example of a radiolabeled monoclonal antibody. Monoclonal antibodies are given by infusion.[northshore.org] […] and IKKβ, ii) degradation and phosphorylation of IκBα, iii) JunB and JunD, iv) total and phospho-protein levels of Akt, v) phosphorylation of RelA, vi) heat shock protein 90[ncbi.nlm.nih.gov] More patients were aged 90 years (2.6 %), in this study, than in a nationwide survey ( KEYWORDS: Adult T-cell leukemia–lymphoma; Okinawa; Retrospective analysis; Strongyloidiasis[ncbi.nlm.nih.gov] 13 , Torimoto Y 14 , Sato K 15 , Iwasaki H 16 , Haseyama Y 17 , Kohda K 18 , Nagamachi Y 19 , Hirayama Y 20 , Sakai H 21 , Hirata Y 22 , Fukuhara T 23 , Ikeda H 2 , Kobune[ncbi.nlm.nih.gov]

  • Alteplase

    R , Cheng G , Chen Q , Zhang Y , Zhou J , Yang J , Liu Y , Xu M , Wei X , Rong L , Liu H , Lv Y , Zhang C , Zhang X , Xia J , Wang H , Zhang Y , Li X , Wang Y , Li X , Lu[ncbi.nlm.nih.gov] Ibritumomab Tiuxetan: (Major) During and after therapy, avoid the concomitant use of Yttrium (Y)-90 ibrutumomab tiuxetan with drugs that interfere with coagulation such as[pdr.net] At 90 days, 122 patients (78.2%) in the alteplase group vs 128 (81.5%) in the aspirin group achieved a favorable outcome (adjusted risk difference, -1.1%; 95% CI, -9.4% to[ncbi.nlm.nih.gov] Patients were randomly assigned to receive low-dose (0.6 mg/kg; 15% as bolus and 85% as infusion over 1 hour) or standard-dose (0.9 mg/kg; 10% as bolus and 90% as infusion[ncbi.nlm.nih.gov] , Uesaka Y , Shiokawa Y , Norihisa D , Hasegawa Y , Takizawa S , Yoshii J , Ito Y , Okuda S , Nagakane Y , Yoshimura S , Sakai N , Todo K , Ohnishi H , Inoue T , Ohyama H[ncbi.nlm.nih.gov]

  • Lymphoma

    Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration.[ncbi.nlm.nih.gov] Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and Drug Administration, and iodine I 131 tositumomab have demonstrated a high level of activity in patients[bloodjournal.hematologylibrary.org] Radioimmunotherapy (also called radiolabeled monoclonal antibody therapy): This therapy pairs a monoclonal antibody with a radioactive material, such as Yttrium-90 with Ibritumomab[radiologyinfo.org] Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade[emedicine.medscape.com] Google Scholar [22] Haecker I., Gay LA., Yang Y., Herpesvirus miRNA function in primary effusion lymphomas, PLoS Pathog., 2012, 8, e1002884.[degruyter.com]

  • Mantle Cell Lymphoma

    Xie Y 1 , Li B 2 , Bu W 1 , Gao L 1 , Zhang Y 2 , Lan X 1 , Hou J 1 , Xu Z 2 , Chang S 1 , Yu D 1 , Xie B 1 , Wang Y 1 , Wang H 1 , Zhang Y 1 , Wu X 1 , Zhu W 2 , Shi J 1[ncbi.nlm.nih.gov] The complete response rate with acalabrutinib was 40% and the partial response rate was 41%. [24] Radioimmunotherapy Both iodine-131–based tositumomab (Bexxar) [25] and yttrium[emedicine.medscape.com] […] chemotherapy, including 6 courses of CHOP (A chemotherapy protocol consists of cyclophosphamide 1.2 g day 1, doxorubicin 80 mg day 1, vindesine 4 mg day1, and prednisone 90[ncbi.nlm.nih.gov] Tamaki M 1 , Wada H 1 , Gomyo A 1 , Hayakawa J 1 , Akahoshi Y 1 , Harada N 1 , Kusuda M 1 , Ishihara Y 1 , Kawamura K 1 , Tanihara A 1 , Sato M 1 , Terasako-Saito K 1 , Kameda[ncbi.nlm.nih.gov] Overproduction of a protein called cyclin D1 in the lymphoma cells is found in more than 90 percent of patients with MCL.[lymphoma.org]

  • Diffuse Lymphoma

    En este grupo de pacientes es prioritaria la identificación de factores pronósticos clínicos y biológicos que permitan caracterizar grupos de riesgo y establecer posibles[diposit.ub.edu] Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, et al. (2000) Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in[esciencecentral.org] Cerebrospinal fluid MTX levels were above the therapeutic level of 1 X 10(-6) M for at least 20 hours in 90% of courses of combined MTX.[ncbi.nlm.nih.gov] Blood. 1997 Mar 1;89(5):1483-90. Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, Delsol G, Mason DY.[surgpathcriteria.stanford.edu] This might include either rituximab for up to 2 years or treatment with ibritumomab tiuxetan.[cancer.org]